Cardiovascular Systems, Inc. (NASDAQ:CSII) is expected to report first quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate first quarter loss of $ 0.22 per share.
Looking ahead, the full year loss are expected at $ 0.41 per share on the revenues of $ 269.39 million.
The Company Outlook
Revenue for 1Q21 are expected in a range of $ 55.00 million ~ $ 58.00 million
Click Here For More Historical Outlooks Of Cardiovascular Systems, Inc.
Previous Quarter Performance
Cardiovascular Systems, Inc. recorded loss for the fourth quarter of $ 0.43 per share, from the revenue of $ 42.55 million. The quarterly revenues dropped 37.64 percent compared with the same quarter last year. According to street consensus, CSII was expected to report 4Q20 loss of $ 0.46 per share from revenue of $ 38.31 million. The bottom line results beat street analysts by $ 0.03 or 6.52 percent, at the same time, top line results outshined analysts by $ 4.24 million or 11.07 percent.
Stock Performance
Shares of Cardiovascular Systems, Inc. traded up $ 0.20 or 0.57 percent on Tuesday, reaching $ 35.33 with volume of 377.50 thousand shares. Cardiovascular Systems, Inc. has traded high as $ 36.54 and has cracked $ 34.97 on the downward trend
According to the previous trading day, closing price of $ 35.33, representing a 35.12 % increase from the 52 week low of $ 26.00 and a 36.38 % decrease over the 52 week high of $ 55.22.
The company has a market capital of $ 1.42 billion and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Cardiovascular Systems, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.csi360.com
Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary OAS, a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions.
